Get the Stockscreener App
3.475
0.14%
-0.005
Evotec Se Adr stock is traded at $3.475, with a volume of 160.16K.
It is down -0.14% in the last 24 hours and down -7.58% over the past month.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
See More
Previous Close:
$3.48
Open:
$3.51
24h Volume:
160.16K
Relative Volume:
1.07
Market Cap:
$1.24B
Revenue:
$842.96M
Net Income/Loss:
$-185.63M
P/E Ratio:
-6.6077
EPS:
-0.5259
Net Cash Flow:
$-228.52M
1W Performance:
-1.28%
1M Performance:
-7.58%
6M Performance:
-8.79%
1Y Performance:
-22.43%
1-Day Range:
$3.4697
$3.51
1-Week Range:
$3.4697
$3.69
52-Week Range:
$2.84
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.485 | 1.24B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.39 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.17 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.19 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.14 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.04 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Berenberg | Buy |
| Apr-24-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Oct-07-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jul-29-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-11-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
Antibody Optimization Service (Affinity Maturation, Humanization, Phage Display, AI-based Computational Optimization) Market Trends Analysis and Growth Forecast Report 2025-2033 - GlobeNewswire Inc.
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? - Finviz
Financial Review: Evotec (NASDAQ:EVO) & Savara (NASDAQ:SVRA) - Defense World
JustEvotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Chartmill
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Chartmill
Taxes of Evotec SE Sponsored ADR – LSX:A0QZ3J - TradingView — Track All Markets
EvotecHow Low A Company May Go While Still Being Attractive (NASDAQ:EVO) - Seeking Alpha
Evotec Aktie | DE0005664809 | ETR:EVT | News & Aktienkurs | FRA:EVT - LYNX Online Broker
Evotec AG Earnings Call: Resilience Amidst Challenges - MSN
Evotec AG Reports Strategic Shift Amid Mixed Performance - MSN
Annual General Meeting - Evotec
Investor Relations - Evotec
Evotec shares tumble 9% as drug discovery segment weakens - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com UK
EVT Stock Price and Chart — XETR:EVT - TradingView
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com UK
Bayer, BioNxt Solutions, Evotec – falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? - kapitalerhoehungen.de
Evotec SE Sponsored ADR Trade Ideas — LSX:A0QZ3J - TradingView — Track All Markets
Evotec Stock: Some Recovery Has Come, Much More Is Expected (NASDAQ:EVO) - Seeking Alpha
Evotec SE (NASDAQ: EVO) Announces Departure of Chief Operating Officer Dr. Craig Johnstone - Kalkine Media
Markets Brief: Are Bank Stocks Expensive? - Morningstar
ProShares Nanotechnology ETF Holdings - Quiver Quantitative
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid By Investing.com - Investing.com South Africa
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar Canada
Earnings call: Evotec SE meets 2023 guidance, appoints new CEO - Investing.com
Evotec and Variant Bio partner to develop fibrosis treatments - Investing.com
Sandoz Group AG-ADR (SDZNY) Stock Price, News & Analyst Forecast - eToro
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
9.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):